KLRK1 and neoplasm: PD-L1 is a direct target gene of the BET family member Brd4, and BET inhibition by JQ-1 has been found to enhance anti-tumor immunity by suppressing the PD-L1 expression on tumor cells and antigen-presenting cells but also through upregulation of NKG2D ligand MICA on tumor cells (33–35).